Table 8. DIANA-mirPath pathway enrichment analysis for miRNAs differentially expressed between normal tissues and cancers of BRCA2 carriers.
| Rank | KEGG pathway | p-value | N of genes | N of miRNAs |
|---|---|---|---|---|
| 1 | Prion diseases | 0.0000 | 1 | 4 |
| 2 | Protein digestion and absorption | 0.0000 | 33 | 13 |
| 3 | Amoebiasis | 0.0000 | 44 | 15 |
| 4 | Axon guidance | 0.0000 | 70 | 17 |
| 5 | ECM-receptor interaction | 0.0000 | 31 | 17 |
| 6 | Small cell lung cancer | 0.0000 | 46 | 17 |
| 7 | Long-term potentiation | 0.0000 | 43 | 18 |
| 8 | ErbB signaling pathway | 0.0000 | 53 | 19 |
| 9 | Ubiquitin mediated proteolysis | 0.0000 | 76 | 19 |
| 10 | Insulin signaling pathway | 0.0000 | 70 | 19 |
| 14 | MAPK signaling pathway | 0.0000 | 126 | 25 |
| 15 | Pathways in cancer | 0.0000 | 176 | 26 |
| 19 | PI3K-Akt signaling pathway | 0.0000 | 197 | 36 |
| 20 | Wnt signaling pathway | 0.0000 | 101 | 38 |
| 22 | TGF-beta signaling pathway | 0.0000 | 49 | 18 |
| 27 | p53 signaling pathway | 0.0000 | 40 | 19 |
| 31 | Transcriptional misregulation in cancer | 0.0000 | 76 | 20 |
| 53 | HIF-1 signaling pathway | 0.0010 | 46 | 10 |